References
- Cancer Registry of Norway. Cancer in Norway 2018 - Cancer incidence, m., survival and prevalence inNorway. Oslo: Cancer Registry of Norway; 2019.
- Dasgupta T, Bowden L, Berg JW. Malignant melanoma of unknown primary origin. Surg Gynecol Obstet. 1963;117:341–345.
- Smith JL, Jr., Stehlin JS. Jr., Spontaneous regression of primary malignant melanomas with regional metastases. Cancer. 1965;18(11):1399–1415.
- van Beek EJAH, Balm AJM, Nieweg OE, et al. Treatment of regional metastatic melanoma of unknown primary origin. Cancers (Basel)). 2015;7(3):1543–1553.
- Kibbi N, Kluger H, Choi JN. Melanoma: clinical presentations. Cancer Treat Res. 2016;167:107–129.
- Lee CC, Faries MB, Wanek LA, et al. Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol. 2008;26(4):535–541.
- Egberts F, Bergner I, Krüger S, et al. Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas. Ann Oncol. 2014;25(1):246–250.
- Anbari KK, Schuchter LM, Bucky LP, for the University of Pennsylvania Pigmented Lesion Study Group, et al. Melanoma of unknown primary site: presentation, treatment, and prognosis–a single institution study. University of Pennsylvania pigmented lesion study group. Cancer. 1997;79(9):1816–1821.
- Rødgaard JC, Kjerkegaard U, Sørensen JA, et al. Do melanoma patients with melanoma of unknown primary have better survival than patients with melanoma of known primary? Eur J Plast Surg. 2018;41(2):229–232.
- Milton GW, Shaw HM, McCarthy WH. Occult primary malignant melanoma: factors influencing survival. Br J Surg. 1977;64(11):805–808.
- Lee CC, Faries MB, Wanek LA, et al. Improved survival for stage IV melanoma from an unknown primary site. J Clin Oncol. 2009;27(21):3489–3495.
- Cormier JN, Xing Y, Feng L, et al. Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer. 2006;106(9):2012–2020.
- Bae JM, Choi YY, Kim DS, et al. Metastatic melanomas of unknown primary show better prognosis than those of known primary: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2015;72(1):59–70.
- van der Ploeg APT, Haydu LE, Spillane AJ, et al. Melanoma patients with an unknown primary tumor site have a better outcome than those with a known primary following therapeutic lymph node dissection for macroscopic (clinically palpable) nodal disease. Ann Surg Oncol. 2014;21(9):3108–3116.
- Gullestad H. Axillary lymph node dissection from Norway. Plastic Surgery Resident/American Society of Plastic Surgeons. 2017;(8):34–38.
- Mb A. American joint committee on cancer, American cancer society. AJCC cancer staging manual. 8th edn. IL: American Joint Committee on Cancer, Springer; 2017.
- Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813–1823.
- Al-Ani A. Metastatic melanoma with unknown primary. New Zealand: DermNet; 2018.
- Blessing K, McLaren KM. Histological regression in primary cutaneous melanoma: recognition, prevalence and significance. Histopathology. 1992;20(4):315–322.